Beta Drugs Limited

Beta Drugs Limited (BETA) is a micro-cap Healthcare company valued at ₹1,983 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Beta Drugs Limited last traded at ₹1,790, up 2.27% on the day.

Recent developments

On 2026-07-20, Beta Drugs shares rose 17% after reporting a strong Q1 performance, with net profit rising 41% and margin expansion contributing to the positive sentiment.

Financial performance

The company's annual revenue rose 6.3% to ₹385 crore, while annual net profit fell 1.2% to ₹41 crore. The latest quarter saw revenue jump 25.5% to ₹126 crore and net profit surge 37.4% to ₹16 crore, outperforming the same quarter a year earlier. However, the net profit margin narrowed to 10.8% from 11.6% in the prior year.

Valuation multiples

The stock trades at 43.7 times earnings, a premium to the Healthcare median of 32.0, 9.41 times book value.

Things to watch

The company's net profit margin has declined by 0.8 percentage points year-over-year. Promoter holding fell by 7.63 percentage points in the latest quarter. The stock is 26.2% below its 52-week high. The company has not paid dividends despite repeated profits.

Where it stands

Beta Drugs Limited reported a strong Q1 with net profit up 41% and revenue up 25.5% compared to the same quarter a year earlier. The stock is 26.2% below its 52-week high, and promoter holding dropped by 7.63 percentage points. The company's net profit margin has narrowed to 10.8%.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.